Identification of prognosis markers in pediatric high-risk acute lymphoblastic leukemia

Pediatric Hematology and Oncology

Volumn 22, Issue 7, 2005, Pages 629-643

  Al Lamki, Zakia ^a   Wali, Yasser A ^a   Wasifuddin, Shah M ^a   Zachariah, Mathew ^a   Al Mjeni, Rayhanah ^a   Li, Changping ^b   Muralitharan, Shanmugakonar ^a   Al Kharusi, Khalsa ^a   Gunaratne, Preethi ^b   Peterson, Leif ^b   Gibbs, Richard ^b   Gingras, Marie Claude ^b   Margolin, Judith F ^b,c  

^a SULTAN QABOOS UNIVERSITY   (Oman)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

ALL; CASK; CRSP2; Gene expression profiling; GZMK

Indexed keywords

COMPLEMENTARY DNA; GENE PRODUCT; GRANZYME K; PROTEIN KINASE (CALCIUM,CALMODULIN); PROTEIN SUBUNIT; TRANSCRIPTION FACTOR SP1; TRANSCRIPTION FACTOR SP1 SUBUNIT 2; TUMOR MARKER; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER RELAPSE; CASK GENE; CHILD; CHILDHOOD LEUKEMIA; CHROMOSOME TRANSLOCATION; CLINICAL ARTICLE; COMPLEMENTARY DNA CONCATENATED SEQUENCING; CRSP2 GENE; DNA SEQUENCE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE OVEREXPRESSION; GZMK GENE; HIGH RISK PATIENT; HUMAN; HUMAN CELL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUPPRESSION SUBTRACTIVE HYBRIDIZATION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; MALE; NEOPLASM PROTEINS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECURRENCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 25444523003     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.1080/08880010500199069     Document Type: Article

References (44)

1. Carroll WL, Bhojwani D, Min DJ, et al. Pediatric acute lymphoblastic leukemia. Hematology (Am Soc Hematol Educ Program). 2003;102-131.
2. Pui CH, Relling MV, Downing JR. Mechanisms of disease: acute lymphoblastic leukemia. N Engl J Med. 2004;350:1535-1548.
3. Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM study group. Blood. 2000;95:3310-3322.
4. Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood. 2001;97:1211-1218.
5. Pui CH, Ribeiro RC. International collaboration on childhood leukemia. Int J Hematol. 2003;78:383-389.
6. Metzger ML, Howard SC, Fu LC, et al. Outcome of childhood acute lymphoblastic leukaemia in resource-poor countries. Lancet. 2003;362:706-708.
7. Hoelzer D, Gokbuget N, Ottmann O, et al. Acute lymphoblastic leukemia. Hematology (Am Soc Hematol Educ Program). 2002;162-192.
8. Smith M, Arthur D, Camitta B, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol. 1996;14:18-24.
9. Qiu J, Gunaratne P, Peterson LE, et al. Novel potential ALL low-risk markers revealed by gene expression profiling with new high-throughput SSH-CCS-PCR. Leukemia. 2003;17:1891-1900.
10. Ross ME, Zhou X, Song G, et al. Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood. 2003;102:2951-2959.
11. Hayashi Y. Gene expression profiling in childhood acute leukemia: progress and perspectives. Int J Hematol. 2003;78:414-420.
12. Chiaretti S, Li X, Gentleman R, et al. Gene expression profile of adult T-cell acute lymphoblastic leukemia identifies distinct subsets of patients with different response to therapy and survival. Blood. 2004;103:2771-2778.
13. http://www.who.int/whr2001/2001/archives/2000/en/pdf/Annex1-en.pdf
14. Al-Riyami A, Ebrahim GJ. Genetic blood disorders survey in the Sultanate of Oman. J Trop Pediatr. 2003;49(Suppl 1):i1-20.
15. Brown LC, Knox-Macaulay HH. Analysis of the immunophenotypes of de novo acute lymphoblastic leukaemia (ALL) in the Sultanate of Oman. Leuk Res. 2003;27:649-654.
16. Al-Lamki Z, Wali YA, Wasifuddin SM, et al. Relapsed acute leukemia in children: Oman experience. Pediatr Hematol/Oncol. 2004;21:167-173.
17. Gaynon PS, Bostrom BC, Hutchinson RJ, et al. Duration of hospitalization as a measure of cost on Children's Cancer Group acute lymphoblastic leukemia studies. J Clin Oncol. 2001;19:1916-1925.
18. Jonsson V, Hansen MM, Ljungman P, et al. Pharmacoeconomic considerations in treating patients with acute leukemia. Pharmacoeconomics. 1999;15:167-178.
19. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156-159.
20. Diatchenko L, Lau YF, Campbell AP, et al. Suppression subtractive hybridization: a method for generating differentially regulated or tissue-specific cDNA probes and libraries. Proc Natl Acad Sci USA. 1996;93:6025-6030.
21. Gurskaya NG, Diatchenko L, Chenchik A, et al. Equalizing cDNA subtraction based on selective suppression of polymerase chain reaction: cloning of Jurkat cell transcripts induced by phytohemaglutinin and phorbol 12-myristate 13-acetate. Anal Biochem. 1996;240:90-97.
22. Gingras MC, Margolin JF. Differential expression of multiple unexpected genes during U937 cell and macrophage differentiation detected by suppressive subtractive hyberdization. Exp Hematol. 2000;28:65-76.
23. ΔΔCT method. Methods. 2001;25:402-408.
24. Peterson LE. Factor analysis of cluster-specific gene expression levels from cDNA microarrays. Comp Methods Prog Biomed. 2002;69:179-188.
25. Peterson LE. Software Report: CLUSFAVOR 5.0: hierarchical cluster and principal component analysis of microarray-based transcriptional profiles. Genome Biol. 2002;3: software 0002.1-0002.8.
26. Smyth MJ, Trapani JA. Granzymes: exogenous proteinases that induce target cell apoptosis. Immunol Today. 1995;76:202-206.
27. Baker E, Sayers TJ, Sutherland GR, et al. The genes encoding NK cell granule serine proteases, human tryptase-2 (TRYP2) and human granzyme A (HFSP), both map to chromosome 5q11-q12 and define a new locus for cytotoxic lymphocyte granule tryptases. Immunogenetics. 1994;40:235-237.
28. Sattar R, Ali SA, Abbasi A. Bioinformatics of granzymes: sequence comparison and structural studies on granzyme family by homology modeling. Biochem Biophys Res Commun. 2003;308:726-735.
29. Yamada M, Hirasawa A, Shiojima S, et al. Granzyme A mediates glucocorticoid-induced apoptosis in leukemia cells. FASEB J. 2003;17:1712-1714.
30. Debatin KM. Apoptosis pathways in cancer and cancer therapy. Cancer Immunol Immunother. 2004;53:153-159.
31. Hu W, Kavanagh JJ. Anticancer therapy targeting the apoptotic pathway. Lancet Oncol. 2003;4:721-729.
32. Stevenson D, Laverty HG, Wenwieser S, et al. Mapping and expression analysis of the human CASK gene. Mamm Genome. 2000;11:934-937.
33. Dimitratos SD, Woods DF, Stathakis DG, et al. Signaling pathways are focused at specialized regions of the plasma membrane by scaffolding proteins of the MAGUK family. Bioessays. 1999;21:912-921.
34. Bredt DS. Cell biology. Reeling CASK into the nucleus. Nature. 2000;404:241-242.
35. Wang Q, Lu J, Yang C, et al. CASK and its target gene Reelin were co-upregulated in human esophageal carcinoma. Cancer Lett. 2002;179:71-77.
36. Ryu S, Zhou S, Ladurner AG, et al. The transcriptional cofactor complex CRSP is required for activity of the enhancer-binding protein Sp1. Nature. 1999;397:446-50.
37. Kikkawa E, Hinata M, Keng VW, et al. Sp family members stimulate transcription of the hex gene via interactions with GC boxes. J Biochem (Tokyo). 2001;130:885-891.
38. George A, Morse HC 3rd, Justice MJ. The homeobox gene Hex induces T-cell-derived lymphomas when overexpressed in hematopoietic precursor cells. Oncogene. 2003;22:6764-6773.
39. Hansen GM, Justice MJ. Activation of Hex and mEg5 by retroviral insertion may contribute to mouse B-cell leukemia. Oncogene. 1999;18:6531-6539.
40. Lo Nigro L, Cazzaniga G, Di Catalgo A, et al. Clonal stability in children with acute lymphoblastic leukemia (ALL) who relapsed five or more years after diagnosis. Leukemia. 1999;13:190-195.
41. Schrappe M. Evolution of BFM trials for childhood ALL. Ann Hematol. 2004;83(Suppl 1):S121-S123.
42. Tschentscher F, Prescher G, Horsman DE, et al. Partial deletions of the long and short arm of chromosome 3 point to two tumor suppressor genes in uveal melanoma. Cancer Res. 2001;61:3439-3442.
43. Kettunen E, el-Rifai W, Bjorkqvist AM, et al. A broad amplification pattern at 3q in squamous cell lung cancer - a fluorescence in situ hybridization study. Cancer Genet Cytogenet. 2000;117:66-70.
44. Morishita K, Parganas E, Bartholomew C, et al. The human Evi-1 gene is located on chromosome 3q24-q28 but is not rearranged in three cases of acute nonlymphocytic leukemias containing t(3;5)(25;q34) translocations. Oncogene Res. 1990;5:221-231.